Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
Penumbra, Inc. (NYSE: PEN) reported financial results for Q4 and full year 2021, with Q4 revenue reaching $204.0 million, a 22.2% increase from Q4 2020. Full year revenue totaled $747.6 million, up 32.6% year-over-year. US revenue represented 71% of total revenue, with vascular products growing 30.4% to $113.6 million in Q4. Despite higher operating expenses, non-GAAP operating income was $2.5 million for Q4. The company forecasts 2022 revenue between $860 million and $875 million, indicating 15% to 17% growth.
- Q4 2021 revenue of $204.0 million, up 22.2% YoY.
- Full year 2021 revenue increased 32.6% to $747.6 million.
- Vascular product sales grew 30.4% in Q4 to $113.6 million.
- 2022 revenue projection of $860 million to $875 million, indicating 15% to 17% growth.
- Operating loss of $40.1 million in Q4 2021.
- Total operating expenses were 81.1% of total revenue in Q4 2021.
ALAMEDA, Calif., Feb. 22, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021.
Financial Highlights:
- Revenue of
$204.0 million for the fourth quarter of 2021, an increase of22.2% compared to revenue of$166.9 million for the fourth quarter of 2020, or an increase of23.0% in constant currency (a non-GAAP measure)1. US revenue of$144.5 million for the fourth quarter of 2021 was23.7% above the same period a year ago. - Revenue of
$747.6 million for the full year 2021 compared to revenue of$560.4 million for the full year 2020, or an increase of32.6% in constant currency1. US revenue of$527.8 million for the full year 2021 was31.9% above the same period a year ago.
Fourth Quarter 2021 Financial Results
Total revenue increased to
Gross profit for the fourth quarter of 2021 was
Total operating expenses were
Operating loss was
Full Year 2021 Financial Results
Total revenue increased to
Gross profit for the year ended December 31, 2021 was
Total operating expenses for the year ended December 31, 2021 were
Operating loss was
Full Year 2022 Financial Outlook
Penumbra projects total revenue for 2022 to be in the range of
Webcast and Conference Call Information
Penumbra, Inc. will host a conference call to discuss financial results for the fourth quarter and year ended December 31, 2021 after market close on Tuesday, February 22, 2022 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 330-2443 for domestic callers and international callers (conference id: 4604622), or the webcast can be accessed on the "Events" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for two weeks following the completion of the call.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. The Penumbra logo is a trademark of Penumbra, Inc. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency and b) non-GAAP operating expenses, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP diluted earnings per share ("EPS").
Constant currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.
Non-GAAP operating expenses, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:
- the effects of non-recurring expenses associated with the achievement of R&D milestones for our Thunderbolt product and our Lightning launch;
- the effects of the one-time expense associated with the accelerated vesting of options and the amortization of acquired intangible assets over their estimated useful lives in connection with the Sixense acquisition; and
- the excess tax benefits associated with share-based compensation arrangements.
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.
Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the items referred to above.
The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the impact of the COVID-19 pandemic on our business, results of operations and financial condition; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2021, which we expect to file with the SEC on or before March 1, 2022. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands) | ||||
December 31, | ||||
2021 | 2020 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 59,379 | $ 69,670 | ||
Marketable investments | 195,496 | 195,162 | ||
Accounts receivable, net | 133,940 | 114,608 | ||
Inventories | 263,504 | 219,527 | ||
Prepaid expenses and other current assets | 29,155 | 18,735 | ||
Total current assets | 681,474 | 617,702 | ||
Property and equipment, net | 58,856 | 48,169 | ||
Operating lease right-of-use assets | 131,955 | 41,192 | ||
Finance lease right-of-use assets | 36,276 | 38,065 | ||
Intangible assets, net | 90,618 | 10,639 | ||
Goodwill | 166,388 | 8,372 | ||
Deferred taxes | 65,698 | 50,139 | ||
Other non-current assets | 12,985 | 8,705 | ||
Total assets | $ 1,244,250 | $ 822,983 | ||
Liabilities and Stockholders' Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 13,421 | $ 14,109 | ||
Accrued liabilities | 99,796 | 85,795 | ||
Current operating lease liabilities | 8,267 | 4,697 | ||
Current finance lease liabilities | 1,713 | 1,331 | ||
Total current liabilities | 123,197 | 105,932 | ||
Non-current operating lease liabilities | 137,045 | 44,183 | ||
Non-current finance lease liabilities | 26,523 | 27,066 | ||
Other non-current liabilities | 3,558 | 8,014 | ||
Total liabilities | 290,323 | 185,195 | ||
Stockholders' equity: | ||||
Preferred stock | — | — | ||
Common stock | 37 | 36 | ||
Additional paid-in capital | 910,614 | 598,299 | ||
Accumulated other comprehensive (loss) income | (2,630) | 2,541 | ||
Retained earnings | 45,906 | 40,622 | ||
Total Penumbra, Inc. stockholders' equity | 953,927 | 641,498 | ||
Non-controlling interest | — | (3,710) | ||
Total stockholders' equity | $ 953,927 | $ 637,788 | ||
Total liabilities and stockholders' equity | $ 1,244,250 | $ 822,983 | ||
Penumbra, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) | ||||||||
Three Months Ended December 31, | Year Ended December 31, | |||||||
2021 | 2020 | 2021 | 2020 | |||||
Revenue | $ 204,011 | $ 166,898 | $ 747,590 | $ 560,412 | ||||
Cost of revenue | 78,564 | 72,585 | 272,208 | 222,237 | ||||
Gross profit | 125,447 | 94,313 | 475,382 | 338,175 | ||||
Operating expenses: | ||||||||
Research and development | 52,004 | 19,455 | 104,552 | 90,049 | ||||
Sales, general and administrative | 113,500 | 76,603 | 378,331 | 287,068 | ||||
Total operating expenses | 165,504 | 96,058 | 482,883 | 377,117 | ||||
(Loss) from operations | (40,057) | (1,745) | (7,501) | (38,942) | ||||
Interest income, net | 21 | 447 | 938 | 1,267 | ||||
Other (expense) income, net | (918) | 787 | (3,939) | (343) | ||||
(Loss) before income taxes | (40,954) | (511) | (10,502) | (38,018) | ||||
(Benefit from) income taxes | (16,321) | (3,143) | (13,125) | (18,761) | ||||
Consolidated net (loss) income | $ (24,633) | $ 2,632 | $ 2,623 | $ (19,257) | ||||
Net loss attributable to non-controlling interest | $ — | $ (1,016) | $ (2,661) | $ (3,555) | ||||
Net (loss) income attributable to Penumbra, Inc. | $ (24,633) | $ 3,648 | $ 5,284 | $ (15,702) | ||||
Net (loss) income attributable to Penumbra, Inc. per share: | ||||||||
Basic | $ (0.66) | $ 0.10 | $ 0.14 | $ (0.44) | ||||
Diluted | $ (0.66) | $ 0.10 | $ 0.14 | $ (0.44) | ||||
Weighted average shares outstanding: | ||||||||
Basic | 37,451,145 | 36,357,495 | 36,764,290 | 35,766,892 | ||||
Diluted | 37,451,145 | 37,453,842 | 37,881,180 | 35,766,892 | ||||
Penumbra, Inc. Reconciliation of GAAP Operating Expenses and GAAP (Loss) Income From Operations to Non-GAAP Operating Expenses and Non-GAAP Operating Income (Loss)1 (unaudited) (in thousands) | ||||||||
Three Months Ended December 31, | Year Ended December 31, | |||||||
2021 | 2020 | 2021 | 2020 | |||||
GAAP operating expenses | $ 165,504 | $ 96,058 | $ 482,883 | $ 377,117 | ||||
GAAP total operating expenses includes the effect of the | ||||||||
Expenses associated with the achievement of Thunderbolt R&D milestones and Lightning launch, respectively | 15,000 | — | 15,000 | 20,652 | ||||
Accelerated vesting of options related to the acquisition of Sixense | 25,760 | — | 25,760 | — | ||||
Amortization of finite lived intangible assets acquired | 1,785 | — | 1,785 | — | ||||
Non-GAAP operating expenses | $ 122,959 | $ 96,058 | $ 440,338 | $ 356,465 | ||||
GAAP (loss) income from operations2 | $ (40,057) | $ (1,745) | $ (7,501) | $ (38,942) | ||||
GAAP (loss) income from operations includes the effect of the following items: | ||||||||
Expenses associated with the achievement of Thunderbolt R&D milestones and Lightning launch, respectively | 15,000 | 15,000 | 20,652 | |||||
Accelerated vesting of options related to the acquisition of Sixense | 25,760 | — | 25,760 | — | ||||
Amortization of finite lived intangible assets acquired | 1,785 | — | 1,785 | — | ||||
Non-GAAP operating income (loss)2 | $ 2,488 | $ (1,745) | $ 35,044 | $ (18,290) | ||||
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. | ||
2 GAAP loss from operations and Non-GAAP operating loss for the three and twelve months ended December 31, 2020 include the one-time unfavorable impact of | ||
Penumbra, Inc. Reconciliation of GAAP Net (Loss) Income and GAAP Diluted EPS to Non-GAAP Net Income (Loss) and Non-GAAP Diluted EPS1 (unaudited) (in thousands, except per share amounts) | ||||||||||||||||
Three Months Ended | Three Months Ended | Year Ended December 31, 2021 | Year Ended December 31, 2020 | |||||||||||||
Net (loss) income | Diluted | Net | Diluted | Net | Diluted | Net loss4 | Diluted | |||||||||
GAAP net (loss) income | $ (24,633) | $ (0.66) | $ 3,648 | $ 0.10 | $ 5,284 | $ 0.14 | $ (15,702) | $ (0.44) | ||||||||
GAAP net (loss) income includes the effect of the | ||||||||||||||||
Expenses associated with the achievement of Thunderbolt R&D milestones and Lightning launch, respectively | 15,000 | 0.39 | — | — | 15,000 | 0.40 | 20,652 | 0.57 | ||||||||
Accelerated vesting of options related to the acquisition of Sixense2 | 25,760 | 0.68 | — | — | 25,760 | 0.67 | — | — | ||||||||
Amortization of finite lived intangible assets acquired | 1,785 | 0.05 | — | — | 1,785 | 0.05 | — | — | ||||||||
Tax effect on the non-GAAP adjustments above2 | (9,045) | (0.23) | — | — | (9,045) | (0.24) | (4,783) | (0.13) | ||||||||
Excess tax benefits related to stock compensation awards | (4,895) | (0.13) | (2,112) | (0.06) | (12,465) | (0.33) | (12,226) | (0.34) | ||||||||
Non-GAAP net income (loss) | $ 3,972 | $ 0.10 | $ 1,536 | $ 0.04 | $ 26,319 | $ 0.69 | $ (12,059) | $ (0.34) | ||||||||
GAAP diluted EPS | $ (0.66) | $ 0.10 | $ 0.14 | $ (0.44) | ||||||||||||
Non-GAAP diluted EPS3 | $ 0.10 | $ 0.04 | $ 0.69 | $ (0.34) | ||||||||||||
Weighted average shares outstanding used to | ||||||||||||||||
GAAP diluted EPS | 37,451,145 | 37,453,842 | 37,881,180 | 35,766,892 | ||||||||||||
Non-GAAP diluted EPS3 | 38,706,721 | 37,453,842 | 37,881,180 | 35,766,892 | ||||||||||||
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. | ||
2For the three and twelve months ended December 31, 2021, management used a combined federal and state tax rate of | ||
3For the purposes of calculating Non-GAAP diluted EPS for the three months ended December 31, 2021, non-GAAP diluted weighted average shares outstanding of 38,706,721 was used, as the Company had non-GAAP net income in the period. | ||
4GAAP and Non-GAAP net loss and diluted EPS for the three and twelve months ended December 31, 2020, include the one-time unfavorable impact of | ||
Penumbra, Inc. Reconciliation of Revenue Change by Geographic Regions to Constant Currency Revenue Growth1 (unaudited) (in thousands) | ||||||||||||||
Three Months Ended December 31, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2021 | 2020 | $ | % | $ | $ | % | ||||||||
United States | $ 144,483 | $ 116,797 | $ 27,686 | 23.7 % | $ — | $ 27,686 | 23.7 % | |||||||
International | 59,528 | 50,101 | 9,427 | 18.8 % | 1,262 | 10,689 | 21.3 % | |||||||
Total | $ 204,011 | $ 166,898 | $ 37,113 | 22.2 % | $ 1,262 | $ 38,375 | 23.0 % | |||||||
Year Ended December 31, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2021 | 2020 | $ | % | $ | $ | % | ||||||||
United States | $ 527,789 | $ 400,270 | $ 127,519 | 31.9 % | $ — | $ 127,519 | 31.9 % | |||||||
International | 219,801 | 160,142 | 59,659 | 37.3 % | (4,395) | 55,264 | 34.5 % | |||||||
Total | $ 747,590 | $ 560,412 | $ 187,178 | 33.4 % | $ (4,395) | $ 182,783 | 32.6 % | |||||||
Penumbra, Inc. Reconciliation of Revenue Change by Product Categories to Constant Currency Revenue Growth1 (unaudited) (in thousands) | ||||||||||||||
Three Months Ended December 31, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2021 | 2020 | $ | % | $ | $ | % | ||||||||
Vascular | $ 113,565 | $ 87,098 | $ 26,467 | 30.4 % | $ 621 | $ 27,088 | 31.1 % | |||||||
Neuro | 90,446 | 79,800 | 10,646 | 13.3 % | 641 | 11,287 | 14.1 % | |||||||
Total | $ 204,011 | $ 166,898 | $ 37,113 | 22.2 % | $ 1,262 | $ 38,375 | 23.0 % | |||||||
Year Ended December 31, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2021 | 2020 | $ | % | $ | $ | % | ||||||||
Vascular | $ 408,878 | $ 267,783 | $ 141,095 | 52.7 % | $ (1,162) | $ 139,933 | 52.3 % | |||||||
Neuro | 338,712 | 292,629 | 46,083 | 15.7 % | (3,233) | 42,850 | 14.6 % | |||||||
Total | $ 747,590 | $ 560,412 | $ 187,178 | 33.4 % | $ (4,395) | $ 182,783 | 32.6 % | |||||||
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. | ||
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-fourth-quarter-and-full-year-2021-financial-results-301487749.html
SOURCE Penumbra, Inc.
FAQ
What were Penumbra's Q4 2021 financial results?
How much did Penumbra earn in full year 2021?
What is Penumbra's revenue guidance for 2022?
What were the major revenue drivers for Penumbra in Q4 2021?
What did Penumbra's operating loss indicate for Q4 2021?
